CINPHA — Cinclus Pharma Holding publ AB Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cinclus Pharma Holding AB (publ) (Cinclus Pharma) is a Sweden-based research based biotech company developing small molecules for the treatment of gastric acid related diseases. The Company is developing linaprazan glurate, which is being developed for the treatment of severe gastroesophageal reflux disease (GERD). The Company's mission is to introduce products impacting standard of care for patients with gastric acid related diseases, underpinned by the superior P-CAB linaprazan glurate. Cinclus Pharma is in an intensive development phase, ramping up the organization and company structure to prepare for growth and the further development of linaprazan glurate. Cinclus Pharma owns the worldwide commercial rights for linaprazan glurate. Secured commercial rights are central in utilizing the process of launching the product in markets worldwide.
Directors
- Last Annual
- Last Interim
- Incorporated
- December 4th, 2017
- Public Since
- June 20th, 2024
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Address
- Kungsbron 1, Level 3, Elevator G, STOCKHOLM, 111 22
- Web
- https://cincluspharma.com/
- Phone
- +46 8133310
- Auditors
Upcoming Events for CINPHA
Similar to CINPHA
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
Dicot Pharma AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:57 UTC, shares in Cinclus Pharma Holding publ AB are trading at SEK10.40. This share price information is delayed by 15 minutes.
Shares in Cinclus Pharma Holding publ AB last closed at SEK10.40 and the price had moved by over the past 365 days. In terms of relative price strength the Cinclus Pharma Holding publ AB share price has matched the FTSE Global All Cap Index by over the past year.
There is no consensus recommendation for this security.
Find out moreCinclus Pharma Holding publ AB does not currently pay a dividend.
Cinclus Pharma Holding publ AB does not currently pay a dividend.
Cinclus Pharma Holding publ AB does not currently pay a dividend.
To buy shares in Cinclus Pharma Holding publ AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK10.40, shares in Cinclus Pharma Holding publ AB had a market capitalisation of .
Here are the trading details for Cinclus Pharma Holding publ AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: CINPHA
Based on an overall assessment of its quality, value and momentum Cinclus Pharma Holding publ AB is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cinclus Pharma Holding publ AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -60.01%.
As of the last closing price of SEK10.40, shares in Cinclus Pharma Holding publ AB were trading -53.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cinclus Pharma Holding publ AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK10.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Cinclus Pharma Holding publ AB's directors